Yao Wangjing, Xu Jiawen, She Xiangjun, Yu Jiangxin, Liang Zhi, Ye Xin, Tao Jiwei, Wu Sulan, Mao Jianbo, Chen Yiqi, Zhang Yun, Shen Lijun
Department of Vitreous and Retinal Center, Affiliated Eye Hospital of Wenzhou Medical University, Hangzhou, China.
Zhejiang Chinese Medical University Affiliated Jiaxing TCM Hospital, Jiaxing, China.
Front Med (Lausanne). 2022 Dec 13;9:1065397. doi: 10.3389/fmed.2022.1065397. eCollection 2022.
This study aimed to summarize the features of perforating scleral vessels (PSVs) in patients with myopic choroidal neovascularization (CNV) (mCNV) using optical coherence tomography angiography (OCTA) and to identify the associations with the response after intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy.
A consecutive series of naïve patients who had mCNV and received intravitreal anti-VEGF therapy with a follow-up duration of 12 months or more were enrolled. The prevalence, location, and branches of PSVs were analyzed. Projection-resolved OCTA (PR-OCTA) was used to analyze the neovascular signals between CNV and PSVs. Best corrected visual acuity (BCVA) and central macular thickness (CMT) were measured. The proportion of CMT change relative to baseline was used to assess therapeutic response.
A total of 44 eyes from 42 patients with mCNV were enrolled. PSVs were identified in 41 out of 44 eyes. Branches were identified in the PSVs of 24 eyes (57.14%), and 20 eyes did not have PSV branches (47.62%). In eight eyes (18.18%), PSVs were adjacent to mCNV, and in 36 eyes (81.82%), PSVs were not adjacent to mCNV. After anti-VEGF therapy for mCNV, BCVA increased ( = 6.119, < 0.001) and CMT decreased ( = 7.664, < 0.001). In the eyes where PSVs were adjacent to mCNV, BCVA improvements ( = 7.649, = 0.009) were poor, and changes in CMT were small.
The eyes with PSVs adjacent to mCNV showed poor therapeutic responses after intravitreal anti-VEGF therapy.
本研究旨在利用光学相干断层扫描血管造影（OCTA）总结近视性脉络膜新生血管（mCNV）患者的穿通性巩膜血管（PSV）特征，并确定其与玻璃体内抗血管内皮生长因子（抗VEGF）治疗后反应的相关性。
纳入一系列连续的初治mCNV患者，这些患者接受了玻璃体内抗VEGF治疗，随访时间为12个月或更长时间。分析PSV的患病率、位置和分支。使用投影分辨OCTA（PR - OCTA）分析CNV和PSV之间的新生血管信号。测量最佳矫正视力（BCVA）和中心黄斑厚度（CMT）。CMT相对于基线的变化比例用于评估治疗反应。
共纳入42例mCNV患者的44只眼。44只眼中有41只眼发现了PSV。24只眼（57.14%）的PSV有分支，20只眼（47.6%）没有PSV分支。8只眼（18.18%）的PSV与mCNV相邻，36只眼（81.82%）的PSV与mCNV不相邻。mCNV患者接受抗VEGF治疗后，BCVA提高（ = 6.119， < 0.001），CMT降低（ = 7.664， < 0.001）。在PSV与mCNV相邻的眼中，BCVA改善较差（ = 7.649， = 0.009），CMT变化较小。
PSV与mCNV相邻的眼在玻璃体内抗VEGF治疗后显示出较差的治疗反应。
